As a part of British Science Week, we are excited to announce that Biocytogen will be attending Milton Park’s Suppliers in Science Exhibition. Come meet our team and learn about how our antibody discovery platforms, preclinical services, and mouse models are accelerating drug development and advancing research across the world.
What is Milton Park?
Milton Park hosts a dynamic community of over 270 life science companies with the shared goal of driving progress in business, science, and technology. Its strategic location within the “Global Triangle” of Oxford, Cambridge, and London, allows it to be the epicenter of research and innovation.
Event Overview
Date: March 10th, 2026
Venue: Bee House, 140 Eastern Ave, Park Dr, Milton, Abingdon OX14 4SB, UK
Event Schedule
For more information, please refer to the Milton Park website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to connecting with you at Abingdon!
